The complaint filed against the NASDAQ-listed firm claims violations of the Securities Exchange Act of 1934, specifically under sections 10(b) and 20(a). According to court filings, ADMA Biologics allegedly engaged in channel stuffing to artificially boost its reported sales activity, rendering the company's public statements during the class period materially misleading. The DJS Law Group is currently representing shareholders seeking to recover losses resulting from these practices. While the firm is actively soliciting lead plaintiffs for the litigation, investors are reminded that serving in that role is not a prerequisite to participate in any potential financial recovery. The litigation targets corporate transparency and governance failures that allegedly shielded the true nature of the company’s business transactions from its shareholders.
ADMA Biologics Faces Class Action Over Alleged Securities Violations
Investors who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, are facing an August 10 deadline to join a class action lawsuit. The legal action centers on allegations that the company deceived the market by inflating sales figures and failing to disclose related party transactions.
Comments (0)
No comments yet. Be the first!